Xvivo Perfusion Ab · OMXSTO:XVIVO
Xvivo Perfusion Ab — Q2 2025 Earnings Presentation
24 slides from Xvivo Perfusion Ab's earnings presentation, Jul 11, 2025
Slide 1: Interim report Q2 2025
Interim report Q2 2025 Earnings call, July 11, 2025
Slide 2: Today's presenters
Today’s presenters Christoffer Kristoffer Rosenblad Nordström CEO CFO DOC ID: Interim report Q2
Slide 3: Q2 Financials – at a glance
Q2 Financials – at a glance Organic growth Net Sales Thoracic Net sales SEK 178 Million Net Sales SEK 105 million -19% Gross margin 86% Sales growth Organic Abdominal Net sales growth -11% Net Sales SEK 52 million Gross margin 68% +19% - Acquired growth 2% - Currency effect -6% - Total growth -15% S
Slide 4: YTD Financials – at a glance
YTD Financials – at a glance Organic growth Net Sales Thoracic Net sales SEK 397 Million Net Sales SEK 247 million -3% Gross margin 84% Sales growth Organic Abdominal Net sales growth 1% Net Sales SEK 109 million Gross margin 65% +23% - Acquired growth 2% - Currency effect -3% - Total growth 0% Serv
Slide 5: Q2 highlights
Q2 highligths Alex Moroianu Heart transplant recipient, AU DOC ID: Interim report Q2
Slide 6: Market update: Lung US
Market update: Lung US Lower activity than expected Lung Transplants US 2020-2025 Slowdown in transplant growth YTD 1000 4000 900 • Flat growth in lung transplants, 5 %, in Q2 vs last year 3500 800 3000 • Cuts in public healthcare funding causes uncertainties and 700 2500 cost pressure 600 Quartely
Slide 7: Market update: Lung US
Market update: Lung US Leadership in EVLP further strengthened Q2: Continued execution on ELVP strategy Aquisition of XPS customers 2025 4 new XPS YTD • Destocking at largest customer Q3/Q4: • EVLP growth at other customers +21 % Q2: 2 Q1: 2* Targeting 3-4 • 2 additional XPS sold additional lung - I
Slide 8: 12-month follow-up results from EU heart trial
12-month follow-up results from EU heart trial Convincing 12-month follow-up data from EU heart trial presented at ISHLT in Boston, April 2025 Clinical superiority further demonstrated: • 76 % risk reduction in severe PGD – the leading cause of mortality after heart transplantion • The risk reductio
Slide 9: Clinical Evidence Liver Assist
Clinical Evidence Liver Assist REDUCED FEWER REDUCED RISK OF BILIARY GRAFT-RELATED RISK OF GRAFT LOSS COMPLICATIONS COMPLICATIONS 64% 74% 73% reduced risk of reduction of severe reduced risk of graft Biliary strictures liver graft-related loss up to 5 years DBD complications* post-Tx* DCD ECD-DBD In
Slide 10: Regulatory & Clinical updates
Regulatory & Clinical updates DOC ID: Interim report Q2
Slide 11: Regulatory approval status in core markets
Regulatory approval status in core markets PMA approval for STEEN Solution STEEN Solution, XPS & STEEN Solution, XPS & & XPS / PERFADEX 510(k) cleared PERFADEX CE marked PERFADEX approved by the TGA Kidney Assist Transport Kidney Assist Transport Kidney Assist Transport 510(k) cleared CE marked appr
Slide 12: Clinical Trial Status & Tentative Timeline
Clinical Trial Status & Tentative Timeline REVIEW & PRECLINICAL CLINICAL MARKET APPROVAL FOLLOW-UP • Patient enrolment completed May 2023 • 204 patients included across 15 centres 12-month 12 month patient Commercial launch across 8 countries patient follow-up completed target Q3 2025* • Results wer
Slide 13: Financial Performance Q2
Financial Performance Q2 DOC ID: Interim report Q2
Slide 14: Net sales and key ratios Q2
Net sales and key ratios Q2 Apr-Jun Apr-Jun YTD YTD SEK Million 2025 2024 2025 2024 Net sales 178 210 396 396 Sales growth, % -15 % 36 % 0% 34 % Whereof organic growth, % -11 % 35 % 1% 34 % Gross profit 133 158 293 293 Gross margin, % 74 % 75 % 74 % 74 % EBIT (adj) 7 33 37 53 EBIT, % (adj) 4% 16 % 9
Slide 15: Thoracic – Q2 Highlights
Organic sales Thoracic – Q2 Highlights growth R12 24% 14% Net sales by Net sales by Net sales by organ Net Sales region product category SEK 105 million (141) 3% 1% Organic growth 27% -19 % (40) 48% 51% Gross margin 6% 67% 86 % (85) 97% Lung Heart Americas Machine perfusion APAC Static preservation
Slide 16: Abdominal – Q2 Highlights
Organic sales Abdominal – Q2 Highlights growth R12 25% Net sales by Net Sales Net sales by organ region SEK 52 million (47) 12% Organic growth 26% 6% 19 % (45) Gross margin 68 % (63) 74% 82% Liver Kidney Americas APAC EMEA Liver Sales Kidney Sales 38million (33) 14million (14) DOC ID: Interim report
Slide 17: Services – Q2 Highlights
Organic sales Services –Q2 Highlights growth R12 -6% Net Sales Net sales by service SEK 21 million (23) 2025 focus: 14% Organ Recovery • Strategic overview Organic growth • Optimize geographical footprint -19 % (11) Acquired growth 2025 focus: 13 % (-) 86% Digital Services • Invest in tech scalabili
Slide 18: EBITDA
EBITDA Q2 2025 EBITDA (adj), by quarter EBITDA (adj), R12 months Comments SEKm SEKm • R12 Trend weakened due to sales 40% 250 40% development in Q2 2025 70 225 35% 35% • SEK/USD ratio will impact EBITDA negatively 60 200 188 due to large portion of sales in the US. As for 183 30% 30% 51 52 175 refer
Slide 19: Cashflow and financial position
Cashflow and financial position Cash flow from Cashflow from Q2 Cashflow operating activities (R12) investing activities • Cash flow from operating R12 SEKm activities SEK 9 million (25) Q2 Q2 YTD YTD 150 • Investments SEK -72 million (-48) +79m SEKm 2025 2024 2025 2024 125 • Financing activities SE
Slide 20: Outlook
Outlook Alex Moroianu Heart transplant recipient, AU
Slide 21: Outlook 2025
Outlook 2025 • Continued high interest in EVLP globally • Focus on activation and supporting utilization • Support rapid patient inclusion in the CAP (Continued Access Protocol for heart in the US) • Expected to meet critical milestones related to product commercialization and market expansion: • Eu
Slide 22: Long term outlook
Long term outlook • The demand for transplants are x 10 of today’s supply • Sales value of machine perfusion vs cold static storage is ~x 10 • Machine perfusion and service models have proven to increase the number of organs used for transplantation • XVIVO has unique, innovative and world leading p
Slide 23: Nobody should die waiting for a new organ
Nobody should die waiting for a new organ Fredrica Höglund Liver transplant recipient, Sweden DOC ID: Interim report Q2
Slide 24: Financial calendar & contacts
Financial calendar & contacts Financial reports 2025/2026 Investor Relations Interim report July – September 2025: October 23, 2025 Christoffer Rosenblad, CEO Telephone: +46 735 19 21 59 Year-end report 2025: January 27, 2026 E-mail: christoffer.rosenblad@xvivogroup.com Interim report January – Marc